Crit Care Med:应激性高苯丙氨酸血症与心脏重症监护病房的死亡率相关

2022-08-20 MedSci原创 MedSci原创

入住ICU的SHP患者预后较差。在未发生SHP的患者中,使用GRS大于或等于2测量出的与SHP相关的基因多态性与随后的SHP和更高的死亡风险相关。

高苯丙氨酸血症预示心血管疾病患者预后不良。然而,在心脏重症监护病房的危重患者中,应激性高苯丙氨酸血症(SHP)的预后价值和相关因素尚不清楚。

近日,危重病医学领域权威杂志Critical Care Medicine上发表了一篇研究文章,这项前瞻性观察研究以中国台湾单中心心脏ICU为主,纳入了20岁以上的急性生理学和慢性健康评估II评分大于等于15分和/或在心脏ICU使用呼吸机支持的患者。

研究人员在受试者入住ICU期间连续测量患者的血浆苯丙氨酸水平,以探讨其对90天死亡率的预后价值。采用基因阵列技术鉴定苯丙氨酸水平≥11.2μmol/dL的SHP相关基因多态性,并建立遗传风险评分(GRS)。研究人员分析了SHP与临床因素和遗传变异的关系,并确定了蝶啶类药物与遗传变异的相关性。

这项研究纳入了497名患者。苯丙氨酸浓度升高与死亡风险增加独立相关。SHP患者的死亡风险高于无SHP患者(logrank=41.13;p<0.001)。SHP与肝肾功能障碍以及四氢生物德林(BH4)合成(CBR1和AKR1C3)和循环(PCBD2)途径的遗传多态性有关。较高的GRSs与较低的BH4生物利用度相关(p<0.05)。在基线时未发生SHP的患者中,GRSs大于或等于2的患者在ICU期间发生SHP的频率更高(31.5%vs16.1%;p=0.001),死亡风险(p=0.004)高于GRSs小于2的患者。在SHP患者的基线,基因变异不能提供额外的预后价值。

由此可见,入住ICU的SHP患者预后较差。在未发生SHP的患者中,使用GRS大于或等于2测量出的与SHP相关的基因多态性与随后的SHP和更高的死亡风险相关。

原始出处:

Wang, Chao-Hung.et al.Stress Hyperphenylalaninemia Is Associated With Mortality in Cardiac ICU: Clinical Factors, Genetic Variants, and Pteridines.critical care medicine.2022.https://journals.lww.com/ccmjournal/Fulltext/9900/Early_Neuromuscular_Electrical_Stimulation_in.4.aspx

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1931956, encodeId=d451193195666, content=<a href='/topic/show?id=b41b8e035f4' target=_blank style='color:#2F92EE;'>#苯丙氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87035, encryptionId=b41b8e035f4, topicName=苯丙氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Wed Feb 08 19:52:45 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368868, encodeId=fa83136886887, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445391, encodeId=cbfa1445391ca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551233, encodeId=9847155123387, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611702, encodeId=00cd1611e0201, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239959, encodeId=e3e412399598c, content=<a href='/topic/show?id=159b9591e9c' target=_blank style='color:#2F92EE;'>#重症#</a>患者的<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>变化,值得申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a>,可以考虑用<a href='/topic/show?id=0a66254e002' target=_blank style='color:#2F92EE;'>#代谢组学#</a>的研究方法去探索!有感兴趣同学,建议试一试, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95917, encryptionId=159b9591e9c, topicName=重症), TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢), TopicDto(id=40957, encryptionId=ca2e4095eaf, topicName=国家自然科学基金), TopicDto(id=25470, encryptionId=0a66254e002, topicName=代谢组学)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 10:00:04 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239950, encodeId=d1a112399502d, content=<a href='/topic/show?id=324210263580' target=_blank style='color:#2F92EE;'>#高苯丙氨酸血症#</a><a href='/topic/show?id=9916959618a' target=_blank style='color:#2F92EE;'>#重症监护#</a>,这是不是预示着代谢发生变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102635, encryptionId=324210263580, topicName=高苯丙氨酸血症), TopicDto(id=95961, encryptionId=9916959618a, topicName=重症监护)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 09:55:21 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1931956, encodeId=d451193195666, content=<a href='/topic/show?id=b41b8e035f4' target=_blank style='color:#2F92EE;'>#苯丙氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87035, encryptionId=b41b8e035f4, topicName=苯丙氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Wed Feb 08 19:52:45 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368868, encodeId=fa83136886887, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445391, encodeId=cbfa1445391ca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551233, encodeId=9847155123387, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611702, encodeId=00cd1611e0201, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239959, encodeId=e3e412399598c, content=<a href='/topic/show?id=159b9591e9c' target=_blank style='color:#2F92EE;'>#重症#</a>患者的<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>变化,值得申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a>,可以考虑用<a href='/topic/show?id=0a66254e002' target=_blank style='color:#2F92EE;'>#代谢组学#</a>的研究方法去探索!有感兴趣同学,建议试一试, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95917, encryptionId=159b9591e9c, topicName=重症), TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢), TopicDto(id=40957, encryptionId=ca2e4095eaf, topicName=国家自然科学基金), TopicDto(id=25470, encryptionId=0a66254e002, topicName=代谢组学)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 10:00:04 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239950, encodeId=d1a112399502d, content=<a href='/topic/show?id=324210263580' target=_blank style='color:#2F92EE;'>#高苯丙氨酸血症#</a><a href='/topic/show?id=9916959618a' target=_blank style='color:#2F92EE;'>#重症监护#</a>,这是不是预示着代谢发生变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102635, encryptionId=324210263580, topicName=高苯丙氨酸血症), TopicDto(id=95961, encryptionId=9916959618a, topicName=重症监护)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 09:55:21 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1931956, encodeId=d451193195666, content=<a href='/topic/show?id=b41b8e035f4' target=_blank style='color:#2F92EE;'>#苯丙氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87035, encryptionId=b41b8e035f4, topicName=苯丙氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Wed Feb 08 19:52:45 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368868, encodeId=fa83136886887, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445391, encodeId=cbfa1445391ca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551233, encodeId=9847155123387, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611702, encodeId=00cd1611e0201, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239959, encodeId=e3e412399598c, content=<a href='/topic/show?id=159b9591e9c' target=_blank style='color:#2F92EE;'>#重症#</a>患者的<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>变化,值得申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a>,可以考虑用<a href='/topic/show?id=0a66254e002' target=_blank style='color:#2F92EE;'>#代谢组学#</a>的研究方法去探索!有感兴趣同学,建议试一试, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95917, encryptionId=159b9591e9c, topicName=重症), TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢), TopicDto(id=40957, encryptionId=ca2e4095eaf, topicName=国家自然科学基金), TopicDto(id=25470, encryptionId=0a66254e002, topicName=代谢组学)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 10:00:04 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239950, encodeId=d1a112399502d, content=<a href='/topic/show?id=324210263580' target=_blank style='color:#2F92EE;'>#高苯丙氨酸血症#</a><a href='/topic/show?id=9916959618a' target=_blank style='color:#2F92EE;'>#重症监护#</a>,这是不是预示着代谢发生变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102635, encryptionId=324210263580, topicName=高苯丙氨酸血症), TopicDto(id=95961, encryptionId=9916959618a, topicName=重症监护)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 09:55:21 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1931956, encodeId=d451193195666, content=<a href='/topic/show?id=b41b8e035f4' target=_blank style='color:#2F92EE;'>#苯丙氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87035, encryptionId=b41b8e035f4, topicName=苯丙氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Wed Feb 08 19:52:45 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368868, encodeId=fa83136886887, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445391, encodeId=cbfa1445391ca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551233, encodeId=9847155123387, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611702, encodeId=00cd1611e0201, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239959, encodeId=e3e412399598c, content=<a href='/topic/show?id=159b9591e9c' target=_blank style='color:#2F92EE;'>#重症#</a>患者的<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>变化,值得申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a>,可以考虑用<a href='/topic/show?id=0a66254e002' target=_blank style='color:#2F92EE;'>#代谢组学#</a>的研究方法去探索!有感兴趣同学,建议试一试, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95917, encryptionId=159b9591e9c, topicName=重症), TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢), TopicDto(id=40957, encryptionId=ca2e4095eaf, topicName=国家自然科学基金), TopicDto(id=25470, encryptionId=0a66254e002, topicName=代谢组学)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 10:00:04 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239950, encodeId=d1a112399502d, content=<a href='/topic/show?id=324210263580' target=_blank style='color:#2F92EE;'>#高苯丙氨酸血症#</a><a href='/topic/show?id=9916959618a' target=_blank style='color:#2F92EE;'>#重症监护#</a>,这是不是预示着代谢发生变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102635, encryptionId=324210263580, topicName=高苯丙氨酸血症), TopicDto(id=95961, encryptionId=9916959618a, topicName=重症监护)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 09:55:21 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-08-21 bioon6
  5. [GetPortalCommentsPageByObjectIdResponse(id=1931956, encodeId=d451193195666, content=<a href='/topic/show?id=b41b8e035f4' target=_blank style='color:#2F92EE;'>#苯丙氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87035, encryptionId=b41b8e035f4, topicName=苯丙氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Wed Feb 08 19:52:45 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368868, encodeId=fa83136886887, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445391, encodeId=cbfa1445391ca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551233, encodeId=9847155123387, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611702, encodeId=00cd1611e0201, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239959, encodeId=e3e412399598c, content=<a href='/topic/show?id=159b9591e9c' target=_blank style='color:#2F92EE;'>#重症#</a>患者的<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>变化,值得申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a>,可以考虑用<a href='/topic/show?id=0a66254e002' target=_blank style='color:#2F92EE;'>#代谢组学#</a>的研究方法去探索!有感兴趣同学,建议试一试, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95917, encryptionId=159b9591e9c, topicName=重症), TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢), TopicDto(id=40957, encryptionId=ca2e4095eaf, topicName=国家自然科学基金), TopicDto(id=25470, encryptionId=0a66254e002, topicName=代谢组学)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 10:00:04 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239950, encodeId=d1a112399502d, content=<a href='/topic/show?id=324210263580' target=_blank style='color:#2F92EE;'>#高苯丙氨酸血症#</a><a href='/topic/show?id=9916959618a' target=_blank style='color:#2F92EE;'>#重症监护#</a>,这是不是预示着代谢发生变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102635, encryptionId=324210263580, topicName=高苯丙氨酸血症), TopicDto(id=95961, encryptionId=9916959618a, topicName=重症监护)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 09:55:21 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1931956, encodeId=d451193195666, content=<a href='/topic/show?id=b41b8e035f4' target=_blank style='color:#2F92EE;'>#苯丙氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87035, encryptionId=b41b8e035f4, topicName=苯丙氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Wed Feb 08 19:52:45 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368868, encodeId=fa83136886887, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445391, encodeId=cbfa1445391ca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551233, encodeId=9847155123387, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611702, encodeId=00cd1611e0201, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239959, encodeId=e3e412399598c, content=<a href='/topic/show?id=159b9591e9c' target=_blank style='color:#2F92EE;'>#重症#</a>患者的<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>变化,值得申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a>,可以考虑用<a href='/topic/show?id=0a66254e002' target=_blank style='color:#2F92EE;'>#代谢组学#</a>的研究方法去探索!有感兴趣同学,建议试一试, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95917, encryptionId=159b9591e9c, topicName=重症), TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢), TopicDto(id=40957, encryptionId=ca2e4095eaf, topicName=国家自然科学基金), TopicDto(id=25470, encryptionId=0a66254e002, topicName=代谢组学)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 10:00:04 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239950, encodeId=d1a112399502d, content=<a href='/topic/show?id=324210263580' target=_blank style='color:#2F92EE;'>#高苯丙氨酸血症#</a><a href='/topic/show?id=9916959618a' target=_blank style='color:#2F92EE;'>#重症监护#</a>,这是不是预示着代谢发生变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102635, encryptionId=324210263580, topicName=高苯丙氨酸血症), TopicDto(id=95961, encryptionId=9916959618a, topicName=重症监护)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 09:55:21 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-08-20 小小医者

    #重症#患者的#代谢#变化,值得申请#国家自然科学基金#,可以考虑用#代谢组学#的研究方法去探索!有感兴趣同学,建议试一试

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1931956, encodeId=d451193195666, content=<a href='/topic/show?id=b41b8e035f4' target=_blank style='color:#2F92EE;'>#苯丙氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87035, encryptionId=b41b8e035f4, topicName=苯丙氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Wed Feb 08 19:52:45 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368868, encodeId=fa83136886887, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445391, encodeId=cbfa1445391ca, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551233, encodeId=9847155123387, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611702, encodeId=00cd1611e0201, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 21 23:52:45 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239959, encodeId=e3e412399598c, content=<a href='/topic/show?id=159b9591e9c' target=_blank style='color:#2F92EE;'>#重症#</a>患者的<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>变化,值得申请<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#国家自然科学基金#</a>,可以考虑用<a href='/topic/show?id=0a66254e002' target=_blank style='color:#2F92EE;'>#代谢组学#</a>的研究方法去探索!有感兴趣同学,建议试一试, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95917, encryptionId=159b9591e9c, topicName=重症), TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢), TopicDto(id=40957, encryptionId=ca2e4095eaf, topicName=国家自然科学基金), TopicDto(id=25470, encryptionId=0a66254e002, topicName=代谢组学)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 10:00:04 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239950, encodeId=d1a112399502d, content=<a href='/topic/show?id=324210263580' target=_blank style='color:#2F92EE;'>#高苯丙氨酸血症#</a><a href='/topic/show?id=9916959618a' target=_blank style='color:#2F92EE;'>#重症监护#</a>,这是不是预示着代谢发生变化?, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102635, encryptionId=324210263580, topicName=高苯丙氨酸血症), TopicDto(id=95961, encryptionId=9916959618a, topicName=重症监护)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Aug 20 09:55:21 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-08-20 小小医者

    #高苯丙氨酸血症##重症监护#,这是不是预示着代谢发生变化?

    0

相关资讯

JAHA:社区暴力犯罪与心血管疾病死亡率之间的关系

从2000年到2014年,芝加哥社区暴力犯罪率的大幅下降与心血管疾病和冠状动脉疾病死亡率的大幅下降有关。

中国68地「高温」突破历史极值!复旦大学:夜晚高温或导致死亡风险增加40-50%

柳叶刀子刊:在日平均气温不变的情况下,热夜暴露可增加40%-50%的死亡风险,即热夜对健康的影响独立于日均温。

Nature子刊:相比中年,老年外科医生手术患者死亡风险反而升高14%!

Scientifc Reports:外科医生年龄与术后并发症/死亡率的关系:队列研究的系统回顾和荟萃分析

JNNP:澳大利亚塔斯马尼亚州大霍巴特多发性硬化症的发病率和患病率增加

多发性硬化(MS)是一种复杂的神经疾病。环境和生活方式因素与多发性硬化症的发病有关,这些因素在多发性硬化症遗传风险增加的患者中尤为重要。澳大利亚塔斯马尼亚州的大霍巴特地区是主要的多发性硬化症流行病学研

Crit Care:血管外肺水含量与死亡率相关

TPTD测量的EVLW值与危重患者的死亡率相关,非存活患者明显高于存活患者。这一结果可能被解释间接证实了在床边通过TPTD估计EVLW的可靠性。

A&R:低血清尿酸盐、身体成分和死亡率之间的关系

评估低低血清尿酸盐(SU)与肌肉减少症的关系,并评估肌肉减少症是否会混淆低SU和死亡率之间的关联。